Tuesday, 23 Apr 2019

You are here

Improved Survival with Renal Transplant in SLE

The Annals of Internal Medicine has published a cohort study of lupus nephritis (LN) patients with end-stage renal disease (ESRD), showing that renal transplantation is associated with improved survival benefit, with a reduction in death from cardiovascular (CV) disease and infection.

A nationwide cohort study analyzed the national database of nearly all patients with ESRD (United States Renal Data System) and looked at those with incident LN-ESRD who were waitlisted for a renal transplant.

Of the 9659 patients with wait-listed LN-ESRD, 5738 (59%) had a renal transplant.

Transplantation was associated with a reduction in:

  • All-cause mortality (adjusted HR, 0.30 [95% CI, 0.27 to 0.33])
  • CV death (adj. HR 0.26 [CI, 0.23 to 0.30]
  • Death from coronary heart disease 0.30 (CI, 0.19 to 0.48) for ,
  • Death from infection 0.41 (CI, 0.32 to 0.52)
  • Death from Sepsis (aHR 0.41 (CI, 0.31 to 0.53) 

Renal transplant was associated with a significant survival benefit and highlights the benefit of timely referral for LN-ESRD patients needing transplantation.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2019 Update to Lupus Management

The goal of SLE treatment is remission or low disease activity and flare prevention. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. Glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent). Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can be tailored to the clinical scenarios and may allow for tapering or discontinuation of GC.

Mortality Risk Factors in Systemic Sclerosis

A French cohort study of 625 systemic sclerosis (SStc) patients has found a significantly increased mortality risk that can be predicted by common clinical variables.

In addition to a multicenter prospective study, investigators performed a metanalysis on SSc standarized mortality ratios (SMR) and hazard ratios of prognosis factors.

Better Tests Ahead in Lupus

The advent of "big data" and "-omics" technologies offers hope that clinicians will soon have better diagnostics for systemic lupus erythematosus, rheumatologists here were told.

GCA Relapse Risk High with Steroids

Prior to the introduction of tocilizumab to manage giant cell arteritis (GCA), glucocorticoids (GC) have been the mainstay of therapy, but has been limited by relapses in disease. A recent metanalysis shows that relapses occur in nearly half of patients and are related to the duration of therapy rather than the initial dose of GC.

A literature review found 34 studies (2,505 patients) from 8 RCTs of GCA patients only treated with GC.

Presenting Features of Early SLE

What clinical features best identify early systemic lupus erythematosus (SLE) patients from mimics?  A multicenter, multinational study aimed to evaluate manifestations at disease onset and to compare early SLE manifestations to those of diseases mimicking SLE.